These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 26433825)

  • 1. Disease kinetics for decision-making in advanced melanoma: a call for scenario-driven strategy trials.
    Grob JJ; Long GV; Schadendorf D; Flaherty K
    Lancet Oncol; 2015 Oct; 16(13):e522-6. PubMed ID: 26433825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of metastasized malignant melanoma].
    Kamanabrou D
    Praxis (Bern 1994); 2001 Mar; 90(10):391-6. PubMed ID: 11305184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Current aspects in the prognosis of advanced melanoma].
    Sirokay-Kohlmeyer J
    Hautarzt; 2018 Mar; 69(3):249-259. PubMed ID: 29396638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemotherapy for melanoma: rational therapeutics in the search for weapons of melanoma destruction.
    Margolin KA
    Cancer; 2004 Aug; 101(3):435-8. PubMed ID: 15274056
    [No Abstract]   [Full Text] [Related]  

  • 5. Chemotherapy and biologic therapies for melanoma: do they work?
    Jilaveanu LB; Aziz SA; Kluger HM
    Clin Dermatol; 2009; 27(6):614-25. PubMed ID: 19880049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
    Robert C; Dummer R; Gutzmer R; Lorigan P; Kim KB; Nyakas M; Arance A; Liszkay G; Schadendorf D; Cantarini M; Spencer S; Middleton MR
    Lancet Oncol; 2013 Jul; 14(8):733-40. PubMed ID: 23735514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial.
    Schmidt H; Suciu S; Punt CJ; Gore M; Kruit W; Patel P; Lienard D; von der Maase H; Eggermont AM; Keilholz U; ;
    J Clin Oncol; 2007 Apr; 25(12):1562-9. PubMed ID: 17443000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [In vitro drug sensitivity profiling in melanoma].
    Ugurel S
    J Dtsch Dermatol Ges; 2008 Jul; 6(7):611. PubMed ID: 18611186
    [No Abstract]   [Full Text] [Related]  

  • 9. LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951).
    Agarwala SS; Keilholz U; Gilles E; Bedikian AY; Wu J; Kay R; Stein CA; Itri LM; Suciu S; Eggermont AM
    Eur J Cancer; 2009 Jul; 45(10):1807-14. PubMed ID: 19419855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pilot study of high-dose, concurrent biochemotherapy for advanced melanoma.
    Kim KB; Eton O; East MJ; Hodges C; Papadopoulos NE; Grimm EA; Bedikian AY
    Cancer; 2004 Aug; 101(3):596-603. PubMed ID: 15274073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutaneous melanoma: available therapy for metastatic disease.
    Tarhini AA; Agarwala SS
    Dermatol Ther; 2006; 19(1):19-25. PubMed ID: 16405566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tamoxifen vs. non-tamoxifen treatment for advanced melanoma: a meta-analysis.
    Beguerie JR; Xingzhong J; Valdez RP
    Int J Dermatol; 2010 Oct; 49(10):1194-202. PubMed ID: 20883410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What can we learn from phase II adjuvant trials in melanoma?
    Keilholz U; Suciu S; Eggermont AM
    Br J Cancer; 2000 Jul; 83(1):6-7. PubMed ID: 10883660
    [No Abstract]   [Full Text] [Related]  

  • 14. Novel cancer therapies for advanced cutaneous melanoma: The added value of radiomics in the decision making process-A systematic review.
    Guerrisi A; Loi E; Ungania S; Russillo M; Bruzzaniti V; Elia F; Desiderio F; Marconi R; Solivetti FM; Strigari L
    Cancer Med; 2020 Mar; 9(5):1603-1612. PubMed ID: 31951322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The present status of the multidisciplinary treatment of malignant melanoma].
    Ishihara K; Hayasaka K; Ikegawa S; Kageshita T
    Gan No Rinsho; 1985 Jul; 31(9 Suppl):1073-8. PubMed ID: 4057571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy and chemoimmunotherapy for metastatic malignant melanoma: review and recent advances.
    Khayat D; Coeffic D
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():238-47. PubMed ID: 10895160
    [No Abstract]   [Full Text] [Related]  

  • 17. Chemotherapeutics, chemoresistance and the management of melanoma.
    Rass K; Hassel JC
    G Ital Dermatol Venereol; 2009 Feb; 144(1):61-78. PubMed ID: 19218912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [To outwit melanoma with its own tricks].
    Bischoff A
    MMW Fortschr Med; 2003 Apr; 145(15):4-6, 8, 10. PubMed ID: 15104255
    [No Abstract]   [Full Text] [Related]  

  • 19. Chemotherapy for metastatic melanoma.
    Mandarà M; Nortilli R; Sava T; Cetto GL
    Expert Rev Anticancer Ther; 2006 Jan; 6(1):121-30. PubMed ID: 16375649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dacarbazine DTIC and carboplatin as an outpatient treatment for disseminated malignant melanoma.
    Nieboer P; Mulder NH; Van Der Graaf WT; Willemse PH; Hospers GA
    Anticancer Res; 2001; 21(4B):3115-6. PubMed ID: 11712820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.